Westchester Capital Management (New York)’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Westchester Capital Management (New York)’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-460,267	Closed	-$60.7M	–	258
2025 Q1	$60.7M	Buy	+460,267	New	+$57.4M	3.13%	8

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.16B AUM 18.64% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Westchester Capital Management (New York)'s ITCI Position: Q2 2025 in Review

Westchester Capital Management (New York) sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 460,267 shares — an estimated $60.7M sold.

Westchester Capital Management (New York) first reported a position in ITCI in Q1 2025 and held it in 1 quarter. The position peaked at $60.7M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Westchester Capital Management (New York) reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Westchester Capital Management (New York) sold 460,267 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $60.7M.
Westchester Capital Management (New York) first reported a position in Intra-Cellular Therapies Inc. in Q1 2025 and held it in 1 quarter.
Westchester Capital Management (New York)'s Intra-Cellular Therapies Inc. position peaked at $60.7M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Westchester Capital Management (New York)'s 13F filing for Q2 2025, filed 14 Aug 2025.